Model-based DDI Extrapolation Strategy from Adults to Children – A Case Study with Risdiplam
Risdiplam (EVRYSDI) is approved for the treatment of patients with spinal muscular atrophy ≥ 2…
CertaraOctober 7, 2021
FDA’s Digital Transformation: The Future of Technology and How to Prepare
As Life-Science manufacturers embrace new technologies to speed time to market and products become more…
CertaraOctober 5, 2021
The Scary Future of Rare Disease Management
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…
CertaraSeptember 23, 2021
Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers
Drug repurposing is promoted as a cost- and time-effective mechanism for providing new medicines. Often,…
CertaraSeptember 23, 2021
